Related Experiment Video
Updated: May 10, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
The netrin G1 gene rs628117 polymorphism is associated with ischemic stroke
Ani Stepanyan1, Roksana Zakharyan, Anna Boyajyan
1Institute of Molecular Biology, National Academy of Sciences of the Republic of Armenia (NAS RA), Armenia.
Neuroscience Letters
|June 18, 2013
Summary
Genetic variations in synaptic plasticity genes impact stroke outcomes. The Netrin G1 (NTNG1) rs628117 single nucleotide polymorphism’s minor G allele is linked to increased ischemic stroke risk in Armenians.
Area of Science:
- Neuroscience
- Genetics
- Cardiovascular Research
Background:
- Genetic factors influencing synaptic plasticity can affect stroke progression and recovery.
- Netrin G1 (NTNG1), an axonal protein, plays a role in synaptic plasticity.
Purpose of the Study:
- To investigate the association between the Netrin G1 gene rs628117 single nucleotide polymorphism (SNP) and ischemic stroke risk.
- To determine if the NTNG1 rs628117 SNP is a potential risk factor for ischemic stroke in the Armenian population.
Main Methods:
- Genotyping of the NTNG1 rs628117 SNP in 127 ischemic stroke patients and 128 healthy controls from Armenia.
- Utilizing polymerase chain reaction with sequence-specific primers for SNP analysis.
- Statistical analysis performed using Pearson's chi-squared test.
Main Results:
- The NTNG1 rs628117 SNP was found to be implicated in the pathogenesis of ischemic stroke.
- The minor G allele (rs628117*G) of NTNG1 showed a positive association with ischemic stroke.
- Individuals carrying the minor G allele were overrepresented among ischemic stroke patients compared to controls.
Conclusions:
- The minor G allele of the NTNG1 rs628117 SNP is a potential risk factor for ischemic stroke.
- This finding is significant for the Armenian population, suggesting a genetic predisposition.
- Further research may elucidate the precise mechanisms linking NTNG1 variants to stroke risk.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.